Floatz logo

IMMUNOGLOBULIN G2-KAPPA, ANTI-(HOMO SAPIENS DLL4(DELTA-LIKE 4)) AND ANTI-(HOMO SAPIENS VEGFA (VASCULAR ENDOTHELIAL GROWTH FACTOR A,VEGF-A, VEGF)), HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODY, BISPECIFIC

Cancer Ovaries

OncoMed Pharmaceuticals, Inc.monoclonal_antibodyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

525 Active assets in the Cancer Ovaries cohort.

Asset / SponsorPhaseRating
Tisotumab Vedotin
Seagen Inc.
Phase 2BB
TIL
Inge Marie Svane
Phase 2BB
Olaparib
Shandong University
Phase 4BB
Carboplatin
Fudan University
Phase 4BB
Irinotecan
ARCAGY/ GINECO GROUP
Phase 4BB

View all 50 →

Same molecule, other indications

IMMUNOGLOBULIN G2-KAPPA, ANTI-(HOMO SAPIENS DLL4(DELTA-LIKE 4)) AND ANTI-(HOMO SAPIENS VEGFA (VASCULAR ENDOTHELIAL GROWTH FACTOR A,VEGF-A, VEGF)), HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODY, BISPECIFIC is also rated in:

peritoneum cancerDormant
CC
Indicative ·
47 / 100
View asset →
fallopian tube cancerDormant
CC
Indicative ·
47 / 100
View asset →
neoplasmDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →